Pellet Technology in Oral Solid Dosage Forms: Formulation Principles and Applications

Oral Solid Dosage Forms (OSDFs) like tablets and capsules continue to serve as the cornerstone of pharmaceutical drug delivery, valued for their cost-effectiveness and strong patient acceptance. Yet the evolving landscape of New Chemical Entities (NCEs) now presents considerable formulation challenges for pharmaceutical developers. Modern drug discovery frequently produces Highly Potent Active Pharmaceutical Ingredients (HPAPIs) alongside compounds exhibiting inherently problematic characteristics, such as poor aqueous solubility and chemical instability. Addressing these critical limitations, which conventional dosage forms often fail to overcome, has driven a significant shift toward advanced multi-unit delivery systems. Multi-Unit Pellet Systems (MUPs), particularly pellet formulations, have emerged as an important technological solution to these challenges. Pellets are small, free-flowing particles with spherical or semi-spherical geometry, typically measuring between 100 and 1500 μm in diameter for oral drug delivery applications. These particles are manufactured through agglomeration techniques such as extrusion-spheronization, resulting in products with low porosity and a narrow size distribution. The therapeutic and manufacturing advantages of pellet systems are substantial: they enable flexible controlled-release profiles, deliver enhanced content uniformity, and minimize gastrointestinal irritation, ultimately supporting improved patient compliance and therapeutic efficacy.

Formulation and evaluation of pellets: Addressing key challenges

The challenges inherent to modern NCEs, particularly regarding poor solubility and stability, necessitate a pivot toward highly controllable dosage platforms. As a foundational particulate system, pellet technology provides formulators with the inherent modularity, high content uniformity, and robust performance required to transform complex APIs into commercially viable oral solid dosage forms.

Critical API formulation challenges in pellet development

Core advantages and practical applications of pellet formulations

Core Advantages

By leveraging its granular, controlled structure, pellet formulations provide formulators with powerful advantages that enhance efficacy, safety, and manufacturing efficiency. The following core engineering attributes transform complex APIs into predictable, performant solid oral dosage forms:

• Robust pharmacokinetic profile: The small size and consistent transit of individual pellets ensure that the functional coating delivers the API with robust absorption profiles, minimizing dose dumping.
• High content uniformity: The smooth, uniform spheroid surface and narrow size distribution are essential for achieving a precise, homogeneous functional coat and minimizing batch-to-batch release variation.
• Modular drug release: Its core provides a versatile platform, allowing formulators to achieve complex modified-release profiles by selecting the functional polymeric coating system applied.
• Core engineering for stability: Selection of core excipients allows formulators to tailor the mechanical properties (e.g., resistance to crushing) and create a stable microenvironment, protecting the API from moisture or incompatible excipients.

Practical applications

The inherent flexibility of the pellet platform directly addresses specific API challenges through targeted formulation strategies:

• Acid-Labile APIs: These APIs require an enteric coating to survive gastric transit. Pellets are ideal because their large surface area facilitates the application of a uniform enteric coat, and the multi-unit nature reduces the risk of total release failure compared to a single tablet layer.
• Low-Dose potent APIs (e.g., Hormones): For HPAPIs where the dose is extremely small, the uniform size and high content uniformity achievable through pelletization are non-negotiable for ensuring safe and precise therapeutic delivery.
• APIs with unpleasant taste (e.g., Pediatric medications): Pellets allow for effective taste masking via a functional seal coat. The small size makes them easier to swallow, enhancing patient compliance without compromising stability.

Formulation requirements of pellets: The need for advanced coating systems

Manufacturing performant pellets requires precise control over downstream processing to maintain their engineered therapeutic benefits. The transition from individual pellets to commercial dosage forms, whether through encapsulation or compression into Multi-Unit Pellet System (MUPS) tablets, introduces critical manufacturing and stability challenges that can compromise product performance.

These processing steps subject pellets to mechanical stress, moisture exposure, and potential drug migration, all of which threaten the integrity of carefully designed release profiles. Therefore, formulators must implement robust functional film coating systems that preserve the core pellets’ engineered properties while ensuring consistent final product quality and therapeutic efficacy.

This requires careful development of the core pellet properties:

• Pellet size: Size is inversely related to fragility; smaller pellets are generally stronger relative to their size and less affected by compaction, though a larger surface area requires more coating material. Increasing pellet size tends to lead to more coating damage during compression.
• Pellet shape: Pellets with a more irregular shape and rougher surface texture lead to complex compression behavior, resulting in tablets with a more closed pore structure and higher tensile strength.
• Pellet density: Density is crucial for both flow properties and controlled gastric transit, with a specific critical density required to achieve prolonged gastric residence. Furthermore, matching the pellet density and narrow size distribution with those of the excipients prevents segregation and ensures weight uniformity during tableting.

Overcoming processing and flow issues

The transition of bulk pellets into final dosage units is highly susceptible to processing variables, directly impacting product quality and content uniformity.

• Flowability and Electrostatic Charge: The small size and high surface area of free-flowing pellets inherently increase their propensity to acquire electrostatic loading. This charge leads to self-attraction and agglomeration, fundamentally compromising material flow. During high-speed operations like capsule filling, this reduced flow and particle clumping result in inconsistent dosing, leading to wide variations in fill weights and an increased risk of underfilled units.
• Surface Roughness and Dosing Accuracy: The surface roughness and shape of the pellets are critical variables in determining their dosing accuracy during high-speed filling processes. A rough or irregular surface can contribute to reduced flow and inconsistent packing density, leading to inter-unit variability in the final dose

The role of film coating in pellet stabilization

In addition to addressing handling challenges, a functional film coating is essential to impart the required drug release kinetics and stability to the advanced dosage form.

• Functional coating protection : The final coating provides a resilient barrier against mechanical abrasion, moisture, and chemical interaction during downstream processing (e.g., tableting or encapsulation) and throughout the product’s shelf life.
• Product quality and regulatory acceptance: The coating is essential for achieving the required physicochemical quality parameters (e.g., surface smoothness, batch-to-batch color consistency) for final approval and market differentiation. It provides necessary functions like effective color and odor masking while ensuring a rapid disintegration profile for the final dosage form.

SEPIFILM™ : A Functional coating system for pellet protection

To guarantee long-term pellet performance and therapeutic efficacy, a coating system must rigorously address both process performance and physical stability. SEPIFILM™ is the All-in-one coating system designed specifically to achieve these requirements.

A technical functionality in processing

The initial benefit of utilizing a fully formulated coating system like SEPIFILM™ lies in its ability to streamline manufacturing and correct for inherent particulate flow anomalies.

• Process efficiency: As a ready-to-use system, SEPIFILM™ minimizes coating preparation time and ensures batch-to-batch consistency. Its optimized solubility and superior spray properties provide highly uniform film application, which translates directly to reduced batch variability and enhanced process reliability in fluid bed or pan coating equipment.
• Surface modification for Flow: SEPIFILM™ creates a film with a low coefficient of friction and minimal residual tack. This is a critical factor in mitigating electrostatic charging and subsequent agglomeration, thereby ensuring consistent bulk flow properties and maintaining dosing accuracy during high-speed encapsulation or tableting.
• Aesthetic and visual quality: The system achieves a highly uniform, aesthetically acceptable finish with strong opacity at low weight gain. When combined with a ready-to-use coloring agent, formulators gain precise control over color masking, minimizing the risk of batch-to-batch color variability.

Protection of core pellet integrity

The primary functional role of film coatings is physical and chemical protection:

• Mechanical integrity (Seal coat application): When used as a seal coat over an underlying functional layer (e.g., acid-labile or sustained-release polymer), SEPIFILM™ protects the core from abrasion and micro-cracking that can occur during subsequent handling, blending, or compaction. Maintaining this integrity is non-negotiable for ensuring the intended dissolution and release profile remains unaffected.
• Compatibility: The formulation is designed for compatibility with common core pellet materials and standard pharmaceutical processing aids, minimizing the risk of unwanted chemical interaction or adhesion issues during scale-up.

Process control: Validating pellet compatibility with SEPIFILM™

The adoption of any advanced coating system hinges on its proven compatibility and predictable performance across diverse pellet architectures. Empirical validation using Fluidised bed in Wurster configuration technology confirms that SEPIFILM™ establishes a reliable Process Capability necessary for high-volume manufacturing

Studies established that the optimized coating system remains versatile across varying pellet sizes and dispersion viscosities. Crucially, they defined the definitive processing window by identifying the maximum allowable spray flow rate. Adhering to this limit prevents inter-particulate adhesion and agglomeration, a critical failure mode in fluid-bed processing.

By successfully mapping these flow parameters, SEPIFILM™ provides formulators with the necessary process knowledge to guarantee the physical integrity of the microgranules. This process assurance delivers three core functional outcomes: consistent visual quality, effective physical stability, and preserved API dissolution profiles, validating SEPIFILM™ as a robust solution for the pellet platform.

The pellet form is an indispensable solution for modern NCE challenges, offering precision in content uniformity and flexible drug release kinetics. However, the realization of these therapeutic benefits hinges on maintaining pellet integrity throughout downstream processing. SEPIFILM™ addresses this requirement directly by providing comprehensive protection against mechanical stress. This integrated coating solution validates the pellet platform’s full potential, transforming it into a commercially viable system that guarantees manufacturing efficiency and reliable therapeutic outcomes. Achieving these optimized results necessitates rigorous process selection. Effective coat application requires specialized techniques adapted to the modality: the high-efficiency, fully suspended Fluidized bed systems or the cascading, lower-velocity environment of the traditional Coating Pan. SEPIFILM™ ensures precision and consistent quality across these distinct industrial modalities.

Article supplied by Seppic

Sources

1. Contract Pharma, OSD Manufacturing Market: Growth Trends & Outlook, 2025
2. Patheon (Thermo Fisher Scientific), Navigating challenges in HPAPI development and manufacturing, 2025
3. Ranjana Chopra, Fridrun Podczeck, J.Michael Newton, Göran Alderborn, The influence of pellet shape and film coating on the filling of pellets into hard shell capsules 
4. Research and Reviews: Drug Delivery, Multi-Unit Particulate Systems for Rapid Formulation Development of New Chemical Entities, 2022
5. Rok Šibanc, Teja Kitak, Biljana Govedarica, Stanko Srčič, Rok Dreu, Physical properties of pharmaceutical pellets, 2013

Interested in a Seppic sample or do you have any question? Just fill in the form: